31 Julio 2017

OBJECTIVES: To evaluate the effect of bio-oxidative ozone application at the points of greatest pain in patients with chronic masticatory muscle pain.


METHODS: A total number of 40 (40 women, with a mean age of 31.7) were selected after the diagnosis of myofacial pain dysfunction syndrome according to the Research Diagnostic Criteria for Temporomandibular Disorder (RDC/TMD). The patients were randomly divided into two groups; patients received the ozone therapy at the point of greatest pain, ozone group (n = 20); patients received the sham ozone therapy at the point of greatest pain, placebo group (n = 20). Ozone and placebo were applied three times per week, for a total of 6 sessions. Mandibular movements were examined, masticator muscles tenderness were assessed and Pressure Pain Threshold (PPT) values were obtained. Subjective pain levels were evaluated using Visual Analogue Scale (VAS). These assessments were performed at baseline, 1 month and 3 months.


RESULTS: Ozono therapy decreased pain intensity and increased PPT values significantly from baseline to 1 monthand 3 months in Ozone Group (OG) compared with Placebo Group (PG). PPTs of the temporal (OG=24,85±6,65, PG=20,65±5,43, p=.035) and masseter (OG=19,03±6,42, PG=14,23±2,95, p=.007) muscles at 3 months control (T2) were significantly higher in the OG group. PPT value of the lateral pole (LP) was also significantly higher at T2 in the OG group (OG=21,25±8,43, PG=15,35±4,18, p=.012). Mandibular movements did not show significant differences between treatment groups except right lateral excursion (RLE) values at T2 (OG=8,90±1,77, PG=6,85±2,41, p=.003), however, OG demonstrated significanty better results over time. Overall improvements in VAS scores from baseline to 3 months were: OG 67.7%; PG 48,4%.


CONCLUSION: Although ozone therapy can be accepted as an alternative treatment modality in the management of masticatory muscle pain, sham ozone therapy (placebo) showed significant improvements in the tested parameters. This article is protected by copyright. All rights reserved.

13 Octubre 2016

Gaetano Cuccio, Marianno Franzini


Gaetano Cucci

Doctor II Master Oxygen-Ozone University of Pavia, Pavia, Italy


Marianno Franzini

Oxygen-Ozone Therapy Scientific Society, Gorle (BG), Italy




The panniculosis or edematous fibrosclerotic panniculopathy (PEFS), commonly called cellulite is a subcutaneous adipose disease that afflicts the vast majority of women at all ages. PEFS is framed as a subcutaneous adipose suffering from venous and lymphatic stasis whose etiology is multifactorial. Many others are the implications and clinical relapses of diseases of inflammatory or autoimmune basis that determine disease states with involvement of the patient’s general conditions. The oxygen-ozone therapy, thanks to its abilities of improving the rheological properties of the microcirculation, immuno-modulating and anti-inflammatory abnormalities, arises as adjuvant and is a valid method, which is also an alternative compared to conventional protocols.




Cellulite; Oxygen-ozone; Adipose Tissue; Microcirculation.



Más Información

11 Febrero 2015
Added by gregorcuba
Item Type Journal Article
Title [Use of ozone therapy and hydro-pressure technologies in complex intensive therapy of surgical sepsis]
Author Parkhisenko, Iu A
Author Glukhov, A A
Abstract Results of treatment of 214 patients with severe sepsis and septic shock were analyzed. 125 patients treated with various methods of ozonotherapy and hydropressive sanation of infectious foci formed the study group. Control group consisted of 89 patients treated according to generally accepted principles. Comparative analysis of treatment efficacy was carried out with numerous laboratory and instrumental study methods. It is shown that ozonotherapy and hydropressive technologies reduced a lethality from 39.2% in the control group to 25.6% in the study group.
Publication Khirurgiia
Issue 4
Pages 55-58
Date 2001
Journal Abbr Khirurgiia (Mosk)
ISSN 0023-1207
URL http://www.ncbi.nlm.nih.gov/pubmed/11490495
Accessed 2010-02-18 17:27:58
Library Catalog NCBI PubMed
Extra PMID: 11490495